Industry Profile
Annual Report
Helpful Links
Issues
However, as companies and as an industry, we will not succeed if we don't start closing our trust deficit. And we won't accomplish this simply with more effective education efforts or better communications. While those are necessary, they are simply not sufficient in today's environment.
We must rebuild the foundation of trust that we once had and the foundation of trust that we continue to deserve.
And, as we build that foundation of trust, we can do so without compromising our core values. Among them:
- Belief in the power of markets to best determine the value of our medicines
- Support for strong intellectual property protection as a necessary prerequisite for innovation
- Trust in a rigorous, scientifically-based regulatory process to evaluate the safety and effectiveness of our medicines
- Confidence that we have a right – and responsibility – to provide balanced information to prescribers and patients about our medicines
- And commitment to access and serving the needs of society
We know that these values are not only in our best interest – they are in the best interest of the patients that we serve.
Dick ClarkPhRMA Chairman
Importation
It is critical that we maintain our focus on comprehensive health reform to help all Americans access high-quality and affordable healthcare coverage. We should not pursue policies that could expose Americans to substandard drug products and potentially weaken the Food and Drug Administration (FDA) by ...
FDA Issues
Read selected PhRMA comments and other submissions to FDA and other government agencies. This is not intended to provide a complete listing of all PhRMA submissions; in addition, certain submissions may be available in other parts of the PhRMA website.
moreResearch and Development
Everyone with questions about the flu or avian flu should be able to get the answers they need easily and quickly. America's research-based pharmaceutical companies are working actively in partnership with the U.S. Government and world health officials to make sure that patients ...
Direct to Consumer Advertising
PhRMA member companies understand that accurate information about disease and treatment options makes patients and doctors better partners. And getting that information to doctors and patients is the goal of Direct-to-Consumer (DTC) prescription medicine advertising.
DTC advertising increases people's ...
Value of Medicines
The value of new and better medicines stems not only from the improved treatment of disease, but also from a reduction in other health care costs, increased productivity and better quality of life.
more
Prescription Drug Costs
Prescription drugs are the best value in health care - saving lives, reducing pain and suffering, keeping people out of hospitals and nursing homes, and reducing other forms of health care spending.
Cost ...
Intellectual Property
Pharmaceutical companies rely on government-granted patents to protect their huge investments in researching and developing new drugs. It takes 10-15 years and costs $800 million on average to bring a new medicine to market.
Without patents to protect all the inventions necessary to develop ...